Foghorn Therapeutics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $30.9M | $22.6M | $34.2M | $19.2M | $1.3M | $430.0K | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $85.5M | $94.5M | $109.7M | $105.6M | $80.3M | $57.7M | $44.4M |
| SG&A Expense | — | $27.6M | $28.4M | $32.4M | $30.7M | $21.7M | $11.2M | $6.7M |
| Operating Income | — | $-86.4M | $-102.7M | $-107.9M | $-117.1M | $-100.7M | $-68.5M | $-51.1M |
| Operating Margin | — | -279.5% | -454.3% | -315.9% | -609.2% | -7,637.1% | -15,937.4% | — |
| Interest Expense | — | — | — | — | — | $1.9M | $979.0K | $540.0K |
| Pretax Income | — | — | $-86.6M | $-94.2M | $-108.9M | — | — | — |
| Income Tax Expense | — | $0 | $0 | $4.2M | $0 | — | $0 | $0 |
| Net Income | — | $-74.3M | $-86.6M | $-98.4M | $-108.9M | $-101.3M | $-68.8M | $-51.1M |
| Net Margin | — | -240.3% | -383.2% | -288.2% | -566.3% | -7,681.6% | -16,000.0% | — |
| EPS (Basic) | — | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-2.08 | $-4.07 |
| EPS (Diluted) | — | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.73 | $-2.08 | $-4.07 |
| Shares Outstanding (Basic) | 58.7M | 63.0M | 54.9M | 42.0M | 41.6M | 37.2M | 33.1M | 14.6M |
| Shares Outstanding (Diluted) | 58.7M | 63.0M | 54.9M | 42.0M | 41.6M | 37.2M | 33.1M | 14.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |